Skip to content

John Corkery

31 papers in the library · 1,639 citations · publishing 2003-2025

Papers

Sort Most recent Most cited

Phenomenon of new drugs on the Internet: the case of ketamine derivative methoxetamine

Human Psychopharmacology: Clinical and Experimental March 1, 2012 Ornella Corazza, Fabrizio Schifano, Pierluigi Simonato et al. 157 citations

On the basis of the material available both in the scientific literature and on the web, this paper aims to provide a pharmacological, chemical and behavioural overview of the novel compound methoxetamine. This is a dissociative drug related to ketamine, with a much longer duration of action and intensity of effects. A critical discussion of the availability of information on the web of...

DOI: 10.1002/hup.1242 (opens in new tab) Phenomenon The internet Scientific literature Recreation +8

5,6-Methylenedioxy-2-aminoindane: from laboratory curiosity to 'legal high'.

Human Psychopharmacology: Clinical and Experimental March 2012 Cathal T Gallagher, Sulaf Assi, Jacqueline L. Stair et al.

The fully synthetic 'legal high' 5,6-methylenedioxy-2-aminoindane (MDAI) is an analogue of 3,4-methylenedioxymethamphetamine. Although developed in the 1990s, it was not widely abused until 2010. However, mephedrone was banned in the UK in April 2010, and almost immediately, MDAI was widely advertised as a legal alternative. This paper provides both an overview of the current state of knowledge...

Mephedrone (4-methylmethcathinone; 'meow meow'): chemical, pharmacological and clinical issues.

Psychopharmacology April 2011 Fabrizio Schifano, Antonio Albanese, Suzanne Fergus et al.

Recently, those substances deriving from the active ingredient of the Khat plant, cathinone, have been rising in popularity. Indeed, 4-methylmethcathinone (mephedrone; 'meow meow' and others) has been seen by some as a cheaper alternative to other classified recreational drugs. We aimed here at providing a state-of-the-art review on mephedrone history and prevalence of misuse, chemistry,...

Ecstasy (MDMA, MDA, MDEA, MBDB) consumption, seizures, related offences, prices, dosage levels and deaths in the UK (1994–2003)

Journal of Psychopharmacology March 30, 2006 Fabrizio Schifano, John Corkery, Paolo Deluca et al. 96 citations

In the last decade, a global trend of escalating ecstasy (MDMA, MDA, MDEA, MBDB) use was observed. Mentions on medical death certificates, last year's ecstasy use, number of drug offenders, seizures, prices and dosage levels figures were used for this descriptive and correlational study. Figures (1994ñ2003) were taken from the UK General Mortality Registers, from the Home Office Statistical...

New trends in the cyber and street market of recreational drugs? The case of 2C-T-7 ('Blue Mystic').

Journal of Psychopharmacology November 1, 2005 Fabrizio Schifano, Paolo Deluca, Lisa Agosti et al. 70 citations

2C-T-7 ('Blue Mystic'), an illicit compound which shows similarities with MDMA and other designer drugs, has been only occasionally identified in the EU, but discussion on the Internet between experimenters has recently grown significantly. We aimed at collecting together in a review the available information on 2C-T-7, both at the cyber and at the street market level. 2C-T-7 was first...

DOI: 10.1177/0269881105056660 (opens in new tab) Full text (opens in new tab) Online drug trends Digital drug trends Internet drug trends Cyber drug trends +16

Death rates from ecstasy (MDMA, MDA) and polydrug use in England and Wales 1996–2002

Human Psychopharmacology: Clinical and Experimental September 19, 2003 Fabrizio Schifano, Adenekan Oyefeso, John Corkery et al. 93 citations

Abstract The present study reports on all deaths related to taking ecstasy (alone, or in a polydrug combination) occurring in England and Wales in the time frame August 1996–April 2002. Data presented here are based on all information recorded in the National Programme on Substance Abuse Deaths (np‐SAD) database. The np‐SAD regularly receives all information on drug related deaths in addicts...